Regulatory Record in Practice

This openFDA record does not pertain to a new clinical event for Claravis (isotretinoin) by Teva Pharmaceutical Industries Ltd. (TEVA) or its U.S. subsidiary, Teva Pharmaceuticals USA, but rather reaffirms the existing generic approval and marketing status. The FDA approved ANDA 076356 for the 10mg oral capsule on April 11, 2003, and the current NDC 0555-1054 is listed as marketed. The clinical stage is not in development but is marketed, and the AB1 therapeutic equivalence rating indicates that it is a substitutable generic that meets the biopharmaceutical equivalence criteria with the reference listed drug.

Drug and Patient Value

The active ingredient in Claravis, isotretinoin (13-cis-retinoic acid), is an oral retinoid used for the treatment of severe nodular acne. Unlike single-molecule targeted anticancer agents, isotretinoin works through the retinoic acid signaling pathway to reduce sebaceous gland size and differentiation, as well as sebum production and keratinization. The FDA label describes these pharmacological effects at doses of 0.5–1 mg/kg/day. The 2024 American Academy of Dermatology guidelines strongly recommend oral isotretinoin for severe, scarring, or psychosocially burdensome acne, or for patients who have failed standard oral or topical treatments, reinforcing its clinical standing.

Safety and Regulatory Barriers

Isotretinoin is contraindicated during pregnancy due to its strong embryonic and fetal toxicity. All FDA-approved products are subject to the iPLEDGE Risk Evaluation and Mitigation Strategy (REMS), a shared restricted distribution REMS. Introduced in 2005 and approved as a REMS on October 22, 2010, the FDA advisory committee in 2023 recommended, by a vote of 17 to 4 with one abstention, the removal of the 19-day lockout period for patients who missed a prescription refill. On November 30, 2023, the FDA required changes including the allowance of home pregnancy testing, removal of the lockout period, and simplification of some counseling records, aiming to improve access while maintaining pregnancy prevention controls.

Market and Competitive Landscape

The global acne pharmaceutical market is projected to grow from USD 9.2 billion in 2023 to USD 13.1 billion by 2030, with the U.S. accounting for 35.9% of the 2023 global market. Direct competitors include Sun Pharmaceutical Industries' Absorica and Absorica LD, Viatris' Amnesteem, Douglas Pharmaceuticals' Myorisan, Dr. Reddy's Laboratories' Genatrein, and multiple isotretinoin generics. Standard treatments include benzoyl peroxide, topical retinoids, doxycycline, minocycline, sarecycline, and hormonal therapies. Therefore, this record reflects the continued approval and supply of a mature generic product rather than a new approval that would significantly change revenue, and it is interpreted as an asset supporting defensive cash flow in the large dermatology market for Teva.